Tammy Ho, MD
Urology · Irvine, CANPI 1003179128
Payments from drug & device makers
Across 182 payments — averaging $29.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$987
- Boston Scientific$929
- Beckman Coulter, Inc.$389
- Astellas Pharma US Inc$289
- Sumitomo Pharma America, Inc.$253
- Teleflex LLC$242
- plus $2K from 29 others
What the payments were for
- Travel & lodging$2264%
- Food & beverage$4,99792%
- Education$1813%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 49 | $987 |
| Boston Scientific | 18 | $929 |
| Beckman Coulter, Inc. | 2 | $389 |
| Astellas Pharma US Inc | 15 | $289 |
| Sumitomo Pharma America, Inc. | 10 | $253 |
| Teleflex LLC | 8 | $242 |
| Bluewind Medical | 6 | $230 |
| Axonics, Inc. | 4 | $214 |
| Tolmar, Inc. | 8 | $185 |
| Calyxo, Inc. | 3 | $166 |
| Antares Pharma, Inc. | 8 | $152 |
| Merck | 6 | $152 |
| Urogen Pharma, Inc. | 4 | $142 |
| Laborie Medical Technologies Corp. | 1 | $127 |
| Accord Healthcare, Inc. | 5 | $122 |
| Coloplast | 6 | $116 |
| Immunitybio, Inc. | 3 | $66 |
| Halozyme Inc | 3 | $63 |
| Aroa Biosurgery Incorporated | 2 | $62 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $59 |
| Integra Lifesciences Corporation | 2 | $49 |
| Bayer | 2 | $49 |
| Novartis | 2 | $42 |
| Urovant Sciences Inc | 2 | $38 |
| Femselect Inc. | 1 | $37 |
| Tolmar Pharmaceuticals, Inc. | 1 | $31 |
| BD | 1 | $28 |
| Endo USA, Inc. | 1 | $27 |
| Palette Life Sciences, Inc. | 1 | $26 |
| Ferring Pharmaceuticals Inc. | 1 | $25 |
| Endo Pharmaceuticals Inc. | 1 | $24 |
| Myovant Sciences Inc. | 1 | $22 |
| Johnson & Johnson | 1 | $22 |
| Pfizer | 1 | $21 |
| Biotissue Holdings Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AMS$453
- AMS 700$150
- CVAC Aspiration System$129
- Axonics$121
How this compares
$5,404 in reported general payments places this provider in the 65th percentile of 1,324 urology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 342 | $270,128 |
| MyrbetriqMirabegron | 189 | $134,718 |
| Estradiol | 442 | $29,422 |
| PremarinEstrogens, Conjugated | 31 | $13,356 |
| EstringEstradiol | 17 | $8,622 |
| Methenamine Hippurate | 67 | $6,299 |
| Potassium Citrate ErPotassium Citrate | 77 | $6,265 |
| Tamsulosin Hcl | 534 | $5,422 |
| Finasteride | 227 | $3,749 |
| Solifenacin Succinate | 76 | $3,326 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 227 | $2,966 |
| Tolterodine Tartrate ErTolterodine Tartrate | 22 | $2,093 |
| Tadalafil | 27 | $1,487 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 64 | $1,377 |
| Fosfomycin Tromethamine | 13 | $1,209 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $253 | $270,128342 claims |
| Astellas Pharma US IncMyrbetriq | $289 | $134,718189 claims |
| PfizerPremarin, Estring | $21 | $21,97848 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,324 urology providers in California.
Other urology in Irvine
- Edward UchioOrange$21.1M
- Stephen FreedlandWest Hollywood$16.7M
- Alec KooTorrance$7.4M
- Karim ChamieLos Angeles$4.3M
- Ralph ClaymanOrange$3.9M
- Siamak DaneshmandLos Angeles$3.5M
- Arnold ChinLos Angeles$3.5M
- Roger LiLoma Linda$2.3M
- John KowalczykLos Angeles$1.8M
- Arie BelldegrunLos Angeles$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.